MAP2K7 and melanoma: Moreover, the sensitivity towards MAPK-targeting MEK inhibitor treatment was highest in melanoma independent of the presence or absence of genetic MAPK alterations, indicating a disconnection between mutation status and the activity of the MAPK pathway as well as the response to MAPK targeted therapy.